presses animal models of the autoimmune diseases multiple sclerosis, uveitis, and diabetes (6-11). In a double-blind pilot trial involving 30 patients with multiple sclerosis, oral administration of bovine myelin antigens decreased the number of T cells that reacted with myelin basic protein (MBP), with no measurable toxicity (12) . Although favorable trends occurred in the myelin group, clinical efficacy could not be determined because of the small sample size.
Oral administration of native type II collagen ameliorates two animal models of rheumatoid arthritis induced by type II collagen (13) or complete Freund's adjuvant (14) . These experimental findings provided the rationale for a pilot, open-label dose-escalation and safety study in 10 patients with recalcitrant rheumatoid arthritis. Subjects were taken off their immunosuppressive and disease-modifying drugs consisting of methotrexate, 6-mercaptopurine, azathioprine, or auranofin and fed 0.1 mg of solubilized type II collagen daily for 1 month and then switched to 0.5 mg for the next 2 months (15). This dose was extrapolated from experiments in the rat adjuvant arthritis model where feeding 3 to 30 ,ug of collagen attenuated disease (14) and the rat experimental autoimmune encephalomyelitis (EAE) model where feeding 500 to 1000 ,ug of MBP was suppressive (6, 10 ment in the number of swollen joints, the number of tender or painful joints, jointswelling and -tenderness indices, and 15-m walk time at months 1, 2, and 3 in the collagen group as compared with placebo patients, except for the number of tender or painful joints at month 2 (P = 0.06) ( Table  2) . Among the collagen patients, the decline in the number of swollen joints, tender joints, and joint-swelling and -tenderness indices were all significant (P < 0.05). Four of the collagen patients (14%), as compared with none in the placebo group, had complete resolution of disease (27). Table 3 indicates the patients' status by other outcome measures (16, 21, 28). Stability or improvement while patients were off immunosuppressives occurred in the collagen group, whereas patients in the placebo group tended to deteriorate. In alternative analyses that reduce the influence of the four placebo patients who withdrew from the trial (25), a similar significant (P e 0.05) improvement from collagen was seen (29). A placebo effect resembling that encountered in other RA trials (30) was also observed. Four patients (13%) in the placebo group exhibited substantial benefit (16) and attained functional class I ranking. This observation reaffirms the critical importance of placebo-controlled evaluations in rheumatoid arthritis. No side effects or significant changes in laboratory values, including rheumatoid factor and antibodies to type II collagen, were noted. There was no evidence of sensitization to collagen, as measured by antibodies to type II collagen. Attempts to assess T cell responses to type II collagen, including release of transforming growth factor-4 (TGF-P), were unsuccessful because of the difficulty in demonstrating reactivity to type II collagen in the peripheral blood of RA patients. None of the baseline features, including the presence of collagen antibodies, HLA haplotype, or sex, were associated with responsiveness to collagen (31).
This controlled trial provides evidence that oral administration of small quantities of solubilized native heterologous type II collagen is both safe and can improve the clinical manifestations of active rheumatoid arthritis. Baseline values were determined while 64% of the collagen-treated patients were on immunosuppressive drugs (usually methotrexate or 6-mercaptopurine), and further improvement occurred with collagen treatment. If longer term efficacy is established, oral collagen would be a preferable treatment because it is not toxic. Table 2 . Disease variables in collagen-versus placebo-treated patients.
Differences between physician assessments in collagen and placebo Number of patients (collagen/placebo) evaluated at entry = 28/31, 1 patients were not significant but showed trends in favor of collagen at 1 month = 27/29, 2 months = 26/26, and 3 months = 28/31; withdrawals month (P = 0.066) and 2 months (P = 0.06). Qualitatively similar results were treated as described (25); values shown are differences from entry were found when a two-way analysis of variance was used to adjust for except for patient and physician assessments which are given as prednisone use. Significant improvement was also observed among percentages. There were no significant differences between groups at collagen-treated patients at 1, 2, and 3 months in terms of the number entry (P > 0.05 for all variables by the Wilcoxon rank-sum test or the x2 of swollen joints, the swollen joint index, the number of tender joints, and trend test for patient and physician assessments) (16). Comparisons the tenderness index (Student's t test; all Pvalues are <0.01, except at between groups showed significantly more improvement or less wors-3 months, for the number of swollen joints, P = 0.02, and the swollen ening in the collagen-treated patients (P < 0.05 and P < 0.01).
joint index, P = 0.03). (14) . In all three models, autoimmunity to the toleragen does not appear to initiate disease. Accordingly, our data do not determine whether type II collagen is the primary autoantigen in rheumatoid arthritis.
Mean value
Although initial clinical efficacy of oral collagen has been shown, questions concerning optimum dosing and long-term control of disease remain. Nonetheless, this study demonstrates the therapeutic efficacy of oral tolerance for a human autoimmune disease and provides the foundation for the development of oral collagen as an easily administered nontoxic treatment for rheumatoid arthritis. 
